Phase I/II study of sorafenib in combination with hepatic arterial infusion chemotherapy using low-dose cisplatin and 5-fluorouracil

Liver Cancer

Volumn 4, Issue 4, 2015, Pages 263-273

  Ueshima, Kazuomi ^a   Kudo, Masatoshi ^a   Tanaka, Masatoshi ^b   Kumada, Takashi ^c   Chung, Hobyung ^a   Hagiwara, Satoru ^a   Inoue, Tatsuo ^a   Yada, Norihisa ^a   Kitai, Satoshi ^a  

^a KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b Yokokura Hospital   (Japan)

^c OGAKI MUNICIPAL HOSPITAL   (Japan)

Author keywords

Cisplatin; Fluorouracil; Hepatic arterial infusion; Hepatocellular carcinoma; Sorafenib

Indexed keywords

CISPLATIN; FLUOROURACIL; SORAFENIB;

ADULT; ADVANCED HEPATOCELLULAR CARCINOMA; AGED; ANEMIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; DIARRHEA; DISEASE CONTROL; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG SAFETY; ERYTHEMA MULTIFORME; HAND FOOT SYNDROME; HEPATIC ARTERIAL INFUSION CHEMOTHERAPY; HUMAN; HUMAN TISSUE; HYPERTENSION; LEUKOPENIA; LIVER CELL CARCINOMA; LOSS OF APPETITE; LOW DRUG DOSE; MAXIMUM TOLERATED DOSE; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; SURVIVAL RATE; THROMBOCYTOPENIA; TREATMENT RESPONSE;

EID: 84992180477     PISSN: 22351795     EISSN: 16645553     Source Type: Journal    
DOI: 10.1159/000367751     Document Type: Article

References (43)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM: Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010;127: 2893-2917.
2. CSIJ: http://ganjoho.jp/pro/statistics/en/backnumber/2013-En.html
3. Bartosch B, Thimme R, Blum HE, Zoulim F: Hepatitis C virus-induced hepatocarcinogenesis. J Hepatol 2009;51:810-820.
4. Belghiti J, Fuks D: Liver resection and transplantation in hepatocellular carcinoma. Liver Cancer. 2012; 1:71-82.
5. Shindoh J, Kaseb A, Vauthey JN. Surgical strategy for liver cancers in the era of effective chemotherapy. Liver Cancer. 2013;2:47-54.
6. Rossi S, Di Stasi M, Buscarini E, Quaretti P, Garbagnati F, Squassante L, Paties CT, Silverman DE, Buscarini L: Percutaneous RF interstitial thermal ablation in the treatment of hepatic cancer. Am J Roentgenol 1996;167:759-768.
7. Buscarini L, Buscarini E, Di Stasi M, Vallisa D, Quaretti P, Rocca A: Percutaneous radiofrequency ablation of small hepatocellular carcinoma: long-Term results. Eur Radiol 2001;11:914-921.
8. Lin SM: Local ablation for hepatocellular carcinoma in taiwan. Liver Cancer. 2013;2:73-83.
9. Llovet JM, Real MI, Montana X, Planas R, Coll S, Aponte J, Ayuso C, Sala M, Muchart J, Sola R, Rodes J, Bruix J, Barcelona Liver Cancer Group: Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 2002;359:1734-1739.
10. Lo CM, Ngan H, Tso WK, Liu CL, Lam CM, Poon RT, Fan ST, Wong J: Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 2002;35:1164-1171.
11. Lencioni R: Chemoembolization in patients with hepatocellular carcinoma. Liver Cancer. 2012;1: 41-50.
12. Chan SC: Liver transplantation for hepatocellular carcinoma. Liver Cancer. 2013;2: 338-344.
13. Chan SC, Sharr WW, Chan AC, Chok KS, Lo CM: Rescue Living-Donor Liver Transplantation for Liver Failure Following Hepatectomy for Hepatocellular Carcinoma. Liver Cancer. 2013;2:332-337.
14. Akamatsu N, Sugawara Y, Kokudo N: Living donor liver transplantation for patients with hepatocellular carcinoma. Liver Cancer. 2014;3:108-118.
15. Llovet JM, Burroughs A, Bruix J: Hepatocellular carcinoma. Lancet 2003;362:1907-1917.
16. Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, Burroughs AK, Christensen E, Pagliaro L, Colombo M, Rodes J, EASL Panel of Experts on HCC European Association for the Study of the Liver: Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. J Hepatol 2001;35:421-430.
17. Court WS, Order SE, Siegel JA, Johnson E, DeNittis AS, Principato R, Martz K, Zeiger LS: Remission and survival following monthly intraarterial cisplatinum in nonresectable hepatoma. Cancer Invest 2002;20:613-625.
18. Epirubicin Study Group for Hepatocellular Carcinoma: Intra-Arterial administration of epirubicin in the treatment of nonresectable hepatocellular carcinoma. Cancer Chemother Pharmacol 1987;19:183-189.
19. Ando E, Tanaka M, Yamashita F, Kuromatsu R, Yutani S, Fukumori K, Sumie S, Yano Y, Okuda K, Sata M: Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis: analysis of 48 cases. Cancer 2002;95:588-595.
20. Ando E, Yamashita F, Tanaka M, Tanikawa K: A novel chemotherapy for advanced hepatocellular carcinoma with tumor thrombosis of the main trunk of the portal vein. Cancer 1997;79:1890-1896.
21. Itamoto T, Nakahara H, Tashiro H, Haruta N, Asahara T, Naito A, Ito K: Hepatic arterial infusion of 5-fluorouracil and cisplatin for unresectable or recurrent hepatocellular carcinoma with tumor thrombus of the portal vein. J Surg Oncol 2002;80:143-148.
22. Lai YC, Shih CY, Jeng CM, Yang SS, Hu JT, Sung YC, Liu HT, Hou SM, Wu CH, Chen TK: Hepatic arterial infusion chemotherapy for hepatocellular carcinoma with portal vein tumor thrombosis. World J Gastroenterol 2003;9:2666-2670.
23. Okuda K, Tanaka M, Shibata J, Ando E, Ogata T, Kinoshita H, Eriguchi N, Aoyagi S, Tanikawa K: Hepatic arterial infusion chemotherapy with continuous low dose administration of cisplatin and 5-fluorouracil for multiple recurrence of hepatocellular carcinoma after surgical treatment. Oncol Rep 1999;6:587-591.
24. Tanioka H, Tsuji A, Morita S, Horimi T, Takamatsu M, Shirasaka T, Mizushima T, Ochi K, Kiura K, Tanimoto M: Combination chemotherapy with continuous 5-fluorouracil and low-Dose cisplatin infusion for advanced hepatocellular carcinoma. Anticancer Res 2003;23(2C):1891-1897.
25. Toyoda H, Nakano S, Kumada T, Takeda I, Sugiyama K, Osada T, Kiriyama S, Suga T, Takahashi M: The efficacy of continuous local arterial infusion of 5-fluorouracil and cisplatin through an implanted reservoir for severe advanced hepatocellular carcinoma. Oncology 1995;52:295-299.
26. Yodono H, Sasaki T, Tarusawa K, Midorikawa H, Saito Y, Takekawa SD: Arterial infusion chemotherapy for advanced hepatocellular carcinoma using EPF and EAP therapies. Cancer Chemother Pharmacol 1992;31(Suppl):S89-S92.
27. Wilhelm SM, Carter C, Tang L, Wilkie D, McNabola A, Rong H, Chen C, Zhang X, Vincent P, McHugh M, Cao Y, Shujath J, Gawlak S, Eveleigh D, Rowley B, Liu L, Adnane L, Lynch M, Auclair D, Taylor I, Gedrich R, Voznesensky A, Riedl B, Post LE, Bollag G, Trail PA: BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004;64:7099-7109.
28. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M, Porta C, Zeuzem S, Bolondi L, Greten TF, Galle PR, Seitz JF, Borbath I, Haussinger D, Giannaris T, Shan M, Moscovici M, Voliotis D, Bruix J, SHARP Investigators Study Group: Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359:378-390.
29. Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, Luo R, Feng J, Ye S, Yang TS, Xu J, Sun Y, Liang H, Liu J, Wang J, Tak WY, Pan H, Burock K, Zou J, Voliotis D, Guan Z: Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009;10:25-34.
30. Urabe T, Kaneko S, Matsushita E, Unoura M, Kobayashi K: Clinical pilot study of intrahepatic arterial chemotherapy with methotrexate, 5-fluorouracil, cisplatin and subcutaneous interferon-Alpha-2b for patients with locally advanced hepatocellular carcinoma. Oncology 1998;55:39-47.
31. Kudo M, Izumi N, Kokudo N, Matsui O, Sakamoto M, Nakashima O, Kojiro M, Makuuchi M, HCC Expert Panel of Japan Society of Hepatology: Management of hepatocellular carcinoma in Japan: Consensus-Based Clinical Practice Guidelines proposed by the Japan Society of Hepatology (JSH) 2010 updated version. Dig Dis 2011;29:339-364.
32. Clinical Practice Guidelines for Hepatocellular Carcinoma-The Japan Society of Hepatology 2009 update. Hepatol Res 2010;40(Suppl 1):2-144.
33. Ikai I, Kudo M, Arii S, et al: Report of the 18th follow-up survey of primary liver cancer in Japan. Hepatol Res 2010;40:1043-1059.
34. Yoshikawa M, Ono N, Yodono H, Ichida T, Nakamura H: Phase II study of hepatic arterial infusion of a finepowder formulation of cisplatin for advanced hepatocellular carcinoma. Hepatol Res 2008;38:474-483.
35. Ueshima K, Kudo M, Takita M, Nagai T, Tatsumi C, Ueda T, Kitai S, Ishikawa E, Yada N, Inoue T, Hagiwara S, Minami Y, Chung H: Hepatic arterial infusion chemotherapy using low-Dose 5-fluorouracil and cisplatin for advanced hepatocellular carcinoma. Oncology 2010;78(Suppl 1):148-153.
36. Nagano H, Wada H, Kobayashi S, Marubashi S, Eguchi H, Tanemura M, Tomimaru Y, Osuga K, Umeshita K, Doki Y, Mori M: Long-Term outcome of combined interferon-A and 5-fluorouracil treatment for advanced hepatocellular carcinoma with major portal vein thrombosis. Oncology 2011;80:63-69.
37. Obi S, Yoshida H, Toune R, Unuma T, Kanda M, Sato S, Tateishi R, Teratani T, Shiina S, Omata M: Combination therapy of intraarterial 5-fluorouracil and systemic interferon-Alpha for advanced hepatocellular carcinoma with portal venous invasion. Cancer 2006;106:1990-1997.
38. Yamashita T, Arai K, Sunagozaka H, Ueda T, Terashima T, Yamashita T, Mizukoshi E, Sakai A, Nakamoto Y, Honda M, Kaneko S: Randomized, phase II study comparing interferon combined with hepatic arterial infusion of fluorouracil plus cisplatin and fluorouracil alone in patients with advanced hepatocellular carcinoma. Oncology 2011;81:281-290.
39. Kudo M: Treatment of advanced hepatocellular carcinoma with emphasis on hepatic arterial infusion chemotherapy and molecular targeted therapy. Liver Cancer. 2012;1:62-70.
40. Nouso K, Miyahara K, Uchida D, Kuwaki K, Izumi N, Omata M, Ichida T, Kudo M, Ku Y, Kokudo N, Sakamoto M, Nakashima O, Takayama T, Matsui O, Matsuyama Y, Yamamoto K, Liver Cancer Study Group of Japan: Effect of hepatic arterial infusion chemotherapy of 5-fluorouracil and cisplatin for advanced hepatocellular carcinoma in the Nationwide Survey of Primary Liver Cancer in Japan. Br J Cancer 2013;109:1904-1907.
41. Bruix J, Sherman M, American Association for the Study of Liver Diseases: Management of hepatocellular carcinoma: an update. Hepatology 2011;53:1020-1022.
42. Camma C, Schepis F, Orlando A, Albanese M, Shahied L, Trevisani F, Andreone P, Craxi A, Cottone M: Transarterial chemoembolization for unresectable hepatocellular carcinoma: meta-Analysis of randomized controlled trials. Radiology 2002;224:47-54.
43. Chung YH, Song IH, Song BC, Lee GC, Koh MS, Yoon HK, Lee YS, Sung KB, Suh DJ: Combined therapy consisting of intraarterial cisplatin infusion and systemic interferon-Alpha for hepatocellular carcinoma patients with major portal vein thrombosis or distant metastasis. Cancer 2000;88:1986-1991.